Genetically determined ancestry associates with morphological and molecular carotid plaque features

Authors

Nima Fahim[1*], Tim R. Sakkers[2], Floor B.H. van der Zalm[1], Joost Hoekstra[3], Dominique P.V. de Kleijn[3], Michal Mokry[1], Jose Verdezoto Mosquera[4,5], Gerard Pasterkamp[1], Hester M. den Ruijter[2], Clint L. Miller[4,5], Jessica van Setten[6], Sander W. van der Laan[1,4*].

**These authors contributed equally.*

Affiliations

1 Central Diagnostic Laboratory, Division Laboratories, Pharmacy, and Biomedical genetics, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

2 Laboratory of Experimental Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

3 Department of Vascular Surgery, Division of Surgical Specialties, University Medical Center Utrecht, University of Utrecht, Utrecht, the Netherlands.

4 Department of Genome Sciences, University of Virginia, Charlottesville, VA, USA

5 Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, USA

6 Department of Cardiology, Division Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

Corresponding author(s)
dr. Sander W. van der Laan
Central Diagnostic Laboratory, Division Laboratories, Pharmacy, and Biomedical genetics, University Medical Center Utrecht, Utrecht University, Utrecht
Heidelberglaan 100, 3508 GA, Utrecht, The Netherlands
T: +31 (0) 88 75 565 73
E: s.w.vanderlaan-2@umcutrecht.nl
OrcID: 0000-0001-6888-1404

Manuscript contents
Manuscript of 984 words (max ±800-1000), 1 figure.

Journal subject terms
Genetics, Atherosclerosis, Plaque, Ancestry

Abstract

Atherosclerosis, the main driver of cardiovascular disease (CVD), is influenced by a plethora of risk factors, including age, gender, and diabetes, that correlate with socio-economic status and may vary across ethnicities. These factors fail to fully explain observed ethnic disparities in CVD burden. For example, coronary artery calcification increases with age regardless of ethnicity, yet CAC is more prevalent in individuals of European descent. As these findings may be confounded by self-reported ethnicity, genome-informed ancestry offers a more accurate lens through which to study these ancestral differences. Yet, the biological basis of atherosclerotic plaque development and composition across ancestries remains essential underexplored.

We hypothesized that genetically determined ancestry is associated with morphological and molecular features of atherosclerotic plaques. Leveraging the Athero-Express Biobank Study, an ongoing Dutch cohort with deep histological and transcriptomic profiling of plaques, we analyzed data from 1,944 patients after genotype quality control and ancestry inference using principal component analysis against 1000 Genomes. Two ancestry groups were identified, European (n=1,866) and non-European (n=51), reflecting Netherlands' migratory history.

Demographics were largely comparable between groups, however, ordinal logistic regression showed non-European ancestries had higher odds of increase plaque vulnerability (OR=1.67, 95% CI 1.01-2.77, p = 0.0450), a finding that remained robust after down sampling. Differential gene expression analysis highlighted *NLGN4X* and *CADM3* among the top differentially expressed genes, representing biologically relevant pathways related to synaptic and cell-cell adhesion. Pathway and single-cell enrichment analyses, including through integration with genome-wide association study data, further revealed consistent enrichment of inflammation-related biological processes and diseases.

Our findings support that genetic ancestry correlates with morphological and molecular plaque composition, with non-European patients showing more inflammatory, higher-risk plaque features, including inflammatory signatures. Increased ancestral diversity in vascular biology research is critical for understanding atherosclerotic pathophysiology and develop equitable and personalized therapeutic strategies.

Letter

Cardiovascular disease (CVD) is the primary global cause of death, accounting for nearly 17.9 million deaths annually, with over 75% occurring in low- and middle-income countries[1] . Atherosclerosis, its main driver, is influenced by gender, aging, smoking, hypertension, family history and genetics, type 2 diabetes, lifestyle, and dyslipidemia – risk factors that correlate with socio-economic status and may vary across ethnicities[2–4]. However, they fail to fully explain observed ethnic disparities in relative rates of CVD[3,4]. For example, coronary artery calcification (CAC) – a marker of subclinical atherosclerosis – steadily increases with age, irrespective of gender or ethnicity, yet CAC is more prevalent in individuals of European descent, and more so among men compared to women[3–6]. These results may be confounded by self-reported ethnicity, however, genome-informed ancestry has been shown to correlate with subclinical atherosclerosis[5]. Thus, investigating the biological basis of atherosclerotic plaque development across ancestries remains essential.
Histological analysis is currently the gold standard method to evaluate atherosclerotic plaque composition[7,8]. High-risk lesions are characterized by variable calcific, inflammatory, lipid, and thrombotic components increasing risk of rupture and ischemic events[7,9]. While pathological studies revealed a higher extent of calcified coronary lesions in individuals of European ancestry[8], it remains unclear whether this extends to other morphological[9] or molecular plaque features. We hypothesized that genetically determined ancestry is associated with plaque composition, independent of risk factors.

We leveraged the Athero-Express (AE) biobank study[7] – a Dutch cohort with deep histological and molecular profiling[10–12] of plaques. After quality control and ancestry inference using principal component analysis (PCA, relative to the 1000G phase 3 reference, b38), data for 1,944 patients remained, forming two groups: European (n=1,866) and non-European (n=51), reflecting Netherlands' migratory history[13–15] (Error! Reference source not found.**, panel 1**). Demographics, including age, gender, diabetes prevalence, hypertension, BMI, renal function, cholesterol and hsCRP levels, symptom prevalence and smoking behavior, did not significantly ($p > 0.05$, ***Figure 1*****, panel 2**) differ between Europeans and non-Europeans.

To assess plaque vulnerability, we used the plaque vulnerability index (PVI, a histological score incorporating collagen, macrophages, smooth muscle cells, and lipid content)[7]. Each trait was scored as stable or unstable, yielding a cumulative vulnerability score from 0 to 4. Those with non-European ancestries had higher odds of increased PVI (OR=1.67, 95% CI 1.01-2.77, $p = 0.045$, ***Figure 1*****, panel 3**), even after adjusting for age, gender, year of surgery, and genotyping platform in ordinal logistic regression (OR=1.69, 95% CI 1.01-2.82, $p = 0.047$). Sensitivity analyses using down-sampling (20-fold) of Europeans revealed a median OR=1.13, 95% CI 1.03-1.25, 18/20, $p_{binomial} < 0.001$) indicating our results are robust with regards to the association with PVI. Further dissection of the role of individual plaque composition features revealed that non-Europeans showed lower odds of calcification (OR=0.42, 95% CI 0.21-0.80, $p = 0.009$) and higher odds of macrophage-rich plaques (OR=2.18, 95% CI 1.11-4.26, $p = 0.023$). Which was especially true for male gender: OR=0.75 95% CI 0.61-0.93 $p=0.009$ for calcification, and 1.4 95% CI 1.41-2.15 for macrophages, $p=1.9\times10^{-7}$, respectively. This is consistent with earlier work that men of European descent have increased risk for CAC, underscoring that our study is sufficiently powered to detect established gender-related differences in plaque

composition[6]. Our findings suggest a potential ancestry-related difference in inflammatory versus calcified plaque phenotypes, where non-European patients exhibit higher inflammation (macrophages) and lower mineralization (calcification), consistent with the elevated overall plaque vulnerability observed.

Transcriptomic analyses of 1,028 plaques revealed 1,146 genes differentially expressed ($p_{nominal}<0.05$) out of 13,642 ($p_{binomial} = 1.11x10^{-62}$) between ancestry groups, including *NLGN4X* and *CADM3* ($log_2FC=+0.61$ and +0.94, respectively, FDR < 0.09) linked to synaptic and cell-cell adhesion[16]. Among the top ancestry-associated transcripts, *MON1A*, *NRXN2*, *WHAMM*, and several mitochondrial and Golgi-associated genes showed higher expression in Europeans. In contrast, non-European plaques exhibited higher expression of neuronal adhesion, and immune- and inflammation-related genes including *MMP1*, *NR4A2*, *CADM3*, and *NLGN4X* (Error! Reference source not found.**, panel 4**). To further investigate the underlying mechanisms, we performed gene-set enrichment analyses using fgsea[17] and MSigDB[18] hallmark pathways revealing inflammation-related signatures including epithelial-to-mesenchymal transition, inflammatory response, apoptosis, and coagulation ($p_{adjusted}$ < 0.05). To contextualize the ancestry-associated transcriptional changes we used Enricher[19] to assess enrichment of gene-disease associations (DisGeNET[20]) showing overrepresentation of genes affecting diseases where the immune-driven diseases, such as inflammatory bowel disease, ulcerative colitis, neoplasms, arthritis, and abdominal aortic aneurysms ($p_{adjusted}$ < 0.05). Assessing the enrichment of the DEGs in plaque-derived single-cell RNAseq (n=39, only available of Europeans) data suggest a role for inflammatory cells, specifically macrophages (***Figure 1***, **panel 5**). Enrichment against GWAS Catalog[21] further highlighted associations with circulating myeloid cell traits such as neutrophil-to-lymphocyte ratio, eosinophil percentage and mean corpuscular hemoglobin ($p_{adjusted}$ < 0.05). To assess cardiovascular relevance, we tested for enrichment of ancestry-associated genes against those linked to coronary artery disease[22], CAC[23], and carotid IMT[24] using MAGMA based gene-level GWAS summary statistics[25]. All traits showed higher-than-expected overlap via binomial testing (CAC: 102 nominally significant in CAC GWAS/1,074 nominally significant in our DGEA; CAD: 145/1,077; cIMT: 98/1,077; all $p < 2.3\times10^{-10}$). These complimentary enrichment analyses underscore the robustness of our findings and suggest biological relevance of the ancestry-associated transcriptional difference to atherosclerotic disease.

Despite the strengths of this study – including histological analyses, genetic inference and transcriptomic data – several limitations should be noted. While this is the largest ancestry-focused multimodal study of carotid plaques to date, the small non-European sample limits generalizability. The cohort reflects advanced disease, limiting the extrapolation to earlier subclinical stages of atherosclerosis. Socio-economic status was not directly assessed and may confound ancestry-related differences, although demographics did not differ between ancestry groups.

Our findings support that genetic ancestry is associated with plaque composition with non-European patients showing higher-risk plaque features. Morphological analyses point to increased inflammation and reduced mineralization in non-Europeans, which is supported by transcriptomic data showing broad inflammatory and immune-related transcriptional shifts. Increased representation of diverse ancestries in vascular biology research is critical for understanding atherosclerotic pathophysiology and to improve the design of equitable and personalized therapeutic strategies.



Figure 1: Genetically determined ancestry is associated with morphological and molecular plaque features. The Athero-Express Biobank Study (www.atheroexpress.nl) includes atherosclerotic plaque samples from 3,633 patients undergoing endarterectomy[7]. Routinely plaques are paraffin embedded, decalcified, and histologically and immunohistochemically stained for endothelial cells (CD34),

macrophages (CD68), elastin (Elastic von Giesen, EvG), red blood cell content (Glycophorin C, GlycC), overall structural morphology (Hematoxylin and Eosin, HE), smooth muscle cells (SMA), and collagen (picrosirius red, SR)[7]. A subset of patients (n=1,917) were genotyped in three consecutive experiments using commercial genotyping platforms[10]; community standard quality control as applied[26] and missing genotypes were imputed against the TOPMed reference (b38)[27]. Each experiment was named consecutively: Athero-Express Genomics Study 1, 2, and 3 (AEGS1, AEGS2, AEGS3). From 1,093 plaque samples RNA was isolated in two consecutive experiments, overlapping both histological and genotyped data (n=1,028), and a Celseq2 experimental protocol was adapted for bulk-tissue RNA sequencing described earlier[11]. **(1) Genetic principal component analysis (PCA)** against the 1000G phase 3 (version 5, b38) reference populations. Each population is grouped in a superpopulation: *Admixed American* (purple-pink-tinted bullets) including Mexican Ancestry from Los Angeles USA, Puerto Rican from Puerto Rica, Colombian from Medellian, Colombia, Peruvian from Lima, Peru; *East-Asian* (gray-tinted bullets) including Han Chinese in Bejing, China (CHB), Japanese in Tokyo, Japan (JPT), Southern Han Chinese, China (CHS), Chinese Dai in Xishuanagbanna, China (CDX), and Kinh in Ho Chi Minh City, Vietnam (KVH); *South-Asian* (red-yellow-tinted bullets) including Gujarati Indian from Houston, Texas, Punjabi from Lahore, Pakistan, Bengali from Bangladesh, Sri Lankan Tamil from the UK, and Indian Telugu from the UK; *European* (blue-tinted bullets) including Utah Residents (CEPH) with Northern and Western European ancestry, Toscani in Italia, Finnish in Finland, British in England and Scotland, and Iberian population in Spain; and *African* (green-tinted bullets) including Yoruba in Ibadan, Nigera, Luhya in Webuye, Kenya, Mandinka in The Gambia, Mende in Sierra Leone, Esan in Nigera, American's of African Ancestry in SW USA, and African Carribean in Barbados. The orange-tinted bullets represent the AEGS1, AEGS2 and AEGS3 patients. The PCA revealed two distinct groups, 1,866 patients from European ancestry, and 51 patients from non-European ancestry. **(2) Demographic analyses** revealed no significant differences on risk factors (see main text) between these groups. **(3) Histological analyses** using ordinal and logistics regression, both univariate and multivariate (see text) showed a significant correlated with the plaque vulnerability index (PVI) with non-Europeans having higher odds of increases PVI, i.e. a more unfavorable plaque composition (comprising more intraplaque hemorrhage [IPH], inflammation, more fat content, and fewer collagen, and smooth muscle cells [SMCs]). Sensitivity analyses of individual morphological features, including calcification, macrophage and SMCs, collagen and fat content, and IPH revealed lower odds of calcified plaques and higher odds of inflammatory plaques in non-Europeans. **(4) The differential gene expression analysis** in the samples with both genetic and RNAseq data (n=1,028), utilizing only protein-coding genes mapped against the GRCh38 (hg38) genome assembly with DESeq2 (baseMean > 10), revealed three genes, *NLGN4X*, *NR4A2*, and *CADM3*, significantly differentially expressed when comparing Europeans (reference) with non-Europeans (volcano plot, left, see also text). The heatmap shows the top 30 differentially expressed genes (see text), where *NLGN4X*, *NR4A2*, and *CADM3* are significantly upregulated. Note: For consistency only the results of the multivariate analyses in (3) and (4), corrected for age, gender, genotype platform, and year of surgery, are displayed. **(5) Single-cell RNAseq based** module score analysis of the differentially expressed genes in 39 samples of European ancestry (non-overlapping with the aforementioned 1,028 samples, described elsewhere[25], and a subset is accessible at www.plaqview.com[28]) support the notion of the involvement of inflammatory cells, specifically foam cells, resident macrophages (*Res. Mac.*), and inflammatory macrophages (*Infl. Mac.*), but not T-cells, natural killer cells (NK-cells), memory B-cells (*Mem. B-cells*) or plasma B-cells (*Plas. B-cells*). Created in BioRender. Van der laan, S.W. (2025) https://BioRender.com/yat6tjd.

CREDiT authorship contributions

This is based on the PLoS Genetics format: https://journals.plos.org/plosgenetics/s/authorship#loc-author-contributions

Financial Support

Dr. Sander W. van der Laan is funded through EU H2020 TO_AITION (grant number: 848146), EU HORIZON MIRACLE (grant number: 101115381), and Health~Holland PPP Allowance 'Getting the Perfect Image'. Dr. Clint L. Miller is funded by National Institutes of Health grants (R01HL148239, R01HL164577, and U01DK142283), Leducq Foundation 'COMET' (24CVD02) network, and AHA Transformational Project Award (24TPA1300556). Dr. Sander W. van der Laan, dr. Jessica van Setten, and Dr. Clint L. Miller is funded by CZI Data Insights grant 'MetaPlaq' and EU HORIZON NextGen (grant number: 101136962). Floor B.H. van der Zalm is funded through the Dutch Heart Foundation project 'AtheroNETH'.

Acknowledgements

We are thankful for the support of the Leducq Fondation 'PlaqOmics' (18CDV-02) and 'AtheroGen', and the Chan Zuckerberg Initiative 'MetaPlaq'. The research for this contribution was made possible by the AI for Health working group of the EWUU alliance (https://aiforhealth.ewuu.nl/). The collaborative project 'Getting the Perfect Image' was co-financed through use of PPP Allowance awarded by Health~Holland, Top Sector Life Sciences & Health, to stimulate public-private partnerships.

Disclosures

Dr. Sander W. van der Laan and Gerard Pasterkamp received Roche funding for unrelated work. Roche had no part in this study, neither in the conception, design, and execution of this study, nor in the preparation and contents of this manuscript. Dr. Clint L. Miller received grant support from AstraZeneca for work unrelated to the current study.
ChatGPT for macOS was used to check the text for spelling, grammar and syntax; after use we edited the texts and the authors take full responsibility for the content of this manuscript. Adobe Illustrator 2025 v29.7 (Adobe Inc., San Jose, CA, USA) was used to improve legibility of the fonts in graphs.

Code and data

The data and used for these analyses are available through a Dataverse repository (https://doi.org/10.34894/4IKE3T), and a GitHub repository (https://github.com/CirculatoryHealth/PlaqueMorphology_Ancestry_Public).

References

1. Cardiovascular diseases. https://www.who.int/health-topics/cardiovascular-diseases/.
2. Lusis, A. J. Atherosclerosis. *Nature* **407**, 233–241 (2000).
3. Kronmal, R. A. *et al.* Risk factors for the progression of coronary artery calcification in asymptomatic subjects: results from the Multi-Ethnic Study of Atherosclerosis (MESA). *Circulation* **115**, 2722–2730 (2007).
4. Budoff, M. J. *et al.* Ethnic differences of the presence and severity of coronary atherosclerosis.

Atherosclerosis **187**, 343–350 (2006).
5. Gebreab, S. Y. *et al.* Genetic ancestry is associated with measures of subclinical atherosclerosis in African Americans: the Jackson Heart Study: The Jackson Heart Study. *Arterioscler. Thromb. Vasc. Biol.* **35**, 1271–1278 (2015).
6. Bild, D. E. *et al.* Ethnic differences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). *Circulation* **111**, 1313–1320 (2005).
7. Verhoeven, B. A. N. *et al.* Athero-express: Differential atherosclerotic plaque expression of mRNA and protein in relation to cardiovascular events and patient characteristics. Rationale and design. *Eur. J. Epidemiol.* **19**, 1127–1133 (2004).
8. Otsuka, F., Sakakura, K., Yahagi, K., Joner, M. & Virmani, R. Has our understanding of calcification in human coronary atherosclerosis progressed? *Arterioscler. Thromb. Vasc. Biol.* **34**, 724–736 (2014).
9. van Lammeren, G. W. *et al.* Atherosclerotic Plaque Vulnerability as an Explanation for the Increased Risk of Stroke in Elderly Undergoing Carotid Artery Stenting. *Stroke* **42**, 2550–2555 (2011).
10. van der Laan, S. W. *et al.* Genetic Susceptibility Loci for Cardiovascular Disease and Their Impact on Atherosclerotic Plaques. *Circ Genom Precis Med* **11**, e002115 (2018).
11. Mokry, M. *et al.* Transcriptomic-based clustering of human atherosclerotic plaques identifies subgroups with different underlying biology and clinical presentation. *Nature Cardiovascular Research* **1**, 1140–1155 (2022).
12. Siemelink, M. A. *et al.* Smoking is Associated to DNA Methylation in Atherosclerotic Carotid Lesions. *Circ Genom Precis Med* **11**, e002030 (2018).
13. Hoeveel inwoners hebben een herkomst buiten Nederland. *Centraal Bureau voor de Statistiek* https://www.cbs.nl/nl-nl/dossier/dossier-asiel-migratie-en-integratie/hoeveel-inwoners-hebben-een-herkomst-buiten-nederland.
14. Boomsma, D. I. *et al.* The Genome of the Netherlands: design, and project goals. *Eur. J. Hum. Genet.* **22**, 221–227 (2014).
15. Deelen, P. *et al.* Improved imputation quality of low-frequency and rare variants in European samples using the "Genome of The Netherlands." *Eur. J. Hum. Genet.* **22**, 1321–1326 (2014).
16. Lehr, A. W. *et al.* Phosphorylation of NLGN4X regulates spinogenesis and synaptic function. *eNeuro* **12**, ENEURO.0278-23.2025 (2025).
17. Korotkevich, G. *et al.* Fast gene set enrichment analysis. *bioRxiv* 060012 (2016) doi:10.1101/060012.
18. Liberzon, A. *et al.* The Molecular Signatures Database (MSigDB) hallmark gene set collection. *Cell Syst.* **1**, 417–425 (2015).
19. Xie, Z. *et al.* Gene set knowledge discovery with Enrichr. *Curr. Protoc.* **1**, e90 (2021).
20. Piñero, J. *et al.* DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. *Nucleic Acids Res.* **45**, D833–D839 (2017).
21. Cerezo, M. *et al.* The NHGRI-EBI GWAS Catalog: standards for reusability, sustainability and diversity. *Nucleic Acids Res.* **53**, D998–D1005 (2025).
22. Nelson, C. P. *et al.* Association analyses based on false discovery rate implicate new loci for coronary artery disease. *Nat. Genet.* **49**, 1385–1391 (2017).
23. Kavousi, M. *et al.* Multi-ancestry genome-wide study identifies effector genes and druggable pathways for coronary artery calcification. *Nat. Genet.* **55**, 1651–1664 (2023).
24. Franceschini, N. *et al.* GWAS and colocalization analyses implicate carotid intima-media

thickness and carotid plaque loci in cardiovascular outcomes. *Nat. Commun.* **9**, 5141 (2018).
25. Slenders, L. *et al.* Intersecting single-cell transcriptomics and genome-wide association studies identifies crucial cell populations and candidate genes for atherosclerosis. *Eur Heart J Open* (2021) doi:10.1093/ehjopen/oeab043.
26. Laurie, C. C. *et al.* Quality control and quality assurance in genotypic data for genome-wide association studies. *Genet. Epidemiol.* **34**, 591–602 (2010).
27. Taliun, D. *et al.* Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. *Nature* **590**, 290–299 (2021).
28. Ma, W. F. *et al.* PlaqView 2.0: A comprehensive web portal for cardiovascular single-cell genomics. *Front. Cardiovasc. Med.* **9**, 969421 (2022).

Athero-Express Biobank with 3,633 endarterectomy patients

Includes information on: demographics, arterial stenosis risk factors and multi-omics



Genotyping
n = 1,917

Histopathology
n = 3,633



CD34, CD68, EvG, GlycC, HE, SMA, collagen
+ manual expert histological assessment

RNA Sequencing
n = 1,093



Single-cell RNAseq
n = 39



1. Define Ancestry Groups
Based on Principal Component Analysis



European
n = 1,866

Non-European
n = 51

2. Demographics
European vs. non-European ancestry

no significant differences in demographics and arterial stenosis risk factors, p > 0.05

3. Histological Analysis
Odds in non-European compared with European ancestry

Trait	OR [95% C.I.]	*P*-value
PVI	1.69 [1.01-2.82]	0.047
Calcification	0.42 [0.21-0.80]	0.009
Macrophages	2.18 [1.11-4.27]	0.023
SMCs	1.04 [0.56-1.94]	0.905
Collagen	1.10 [0.51-2.37]	0.801
Fat content	0.82 [0.43-1.54]	0.531
IPH	0.68 [0.38-1.23]	0.205

4. Differential Gene Expression Analysis
European vs. non-European ancestry
13,642 protein coding genes tested





5. Single-cell RNAseq Analysis
In 39 patients of European ancestry



Genetically determined ancestry within the Athero-Express cohort:

- Do **not associate** with demographic and arterial stenosis risk factors
- **Do associate to morphological** and **molecular plaque features**
- **Single-cell RNAseq** suggests a role for inflammatory cells, specifically **macrophage subtypes**

Increased representation of diverse ancestries in vascular biology research is critical for **understanding atherosclerotic pathophysiology** and **improvement of equitable and personalized therapeutic strategies**